Multikinase inhibitors and uses in ocular fibrosis
US11278546B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 21, 2017 |
| Grant date | Mar 22, 2022 |
| Priority date | — |
| Expiry date | Jan 17, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for preventing and/or treating fibrosis associated with an eye-related disease or disorder includes administering an effective amount of a multikinase inhibitor to a subject in need thereof. The multikinase inhibitor is nintedanib, lenvatinib, a combination thereof, or a salt thereof. The eye-related disease or disorder is corneal transparency, corneal scar formation, secondary cataract formation, glaucoma filtration surgery, ocular surgical procedures and implants, photorefractive keratectomy, laser in situ keratomileusis, formation and contraction of pre- and epiretinal membranes, proliferative vitreoretinopathy, subretinal fibrosis/scarring, retinal gliosis, or formation of choroidal membranes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.